Using Machine Learning to Predict Immunotherapy Response

A new machine learning solution could give greater insight on a cancer patient’s response to immunotherapy.

MDDI Staff

July 13, 2022

1 Min Read
Image courtesy of JIRAROJ PRADITCHAROENKUL / Alamy Stock Photo

A research team led by Professor Sanguk Kim (Department of Life Sciences) at POSTECH is gaining attention as they have improved the accuracy of predicting patient response to immune checkpoint inhibitors (ICIs) by using network-based machine learning.

The research team discovered new network-based biomarkers by analyzing the clinical results of more than 700 patients with three different cancers (melanoma, gastric cancer, and bladder cancer) and the transcriptome data of the patients' cancer tissues. By utilizing the network-based biomarkers, the team successfully developed artificial intelligence that could predict the response to anticancer treatment.

The team further proved that the treatment response prediction based on the newly discovered biomarkers was superior to that based on conventional anticancer treatment biomarkers including immunotherapy targets and tumor microenvironment markers.

In their previous study, the research team had developed machine learning that could predict drug responses to chemotherapy in patients with gastric or bladder cancer. This study has shown that artificial intelligence using the interactions between genes in a biological network could successfully predict the patient response to not only chemotherapy, but also immunotherapy in multiple cancer types.

This study helps detect patients who will respond to immunotherapy in advance and establish treatment plans, resulting in customized precision medicine with more patients to benefit from cancer treatments. Supported by the POSTECH Medical Device Innovation Center, the Graduate School of Artificial Intelligence, and ImmunoBiome Inc, this study was recently published in Nature Communications, an international peer-reviewed journal.


Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like